Imbruvica savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Imbruvica

We didn’t find one.

Ask your pharmacy for Imbruvica’s cash price, and one or two other pharmacies too.
Imbruvica’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify myAbbVie Assist. Our income guidelines are based on the size of your household and annual income. Or call 1-800-222-6885.

See if you qualify

Compare every option

Brand nameImbruvica

Authorized genericibrutinib

Regular genericibrutinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Imbruvica?

The original

–

Brand nameThe maker’s card

IMBRUVICA Copay Card (IMBRUVICA By Your Side)

Savings card from AbbVie (Pharmacyclics)

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

The card takes up to $24,600 a year off your co-pay.

Or call 1-844-585-4135.

In the maker’s words

“You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card.”

From the maker’s offer on imbruvica.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Imbruvica itself, from the same company, sold without the brand name, and usually for less. For now Imbruvica is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

IMBRUVICA is a kinase inhibitor indicated for the treatment of:

Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
Adult patients with Waldenström’s macroglobulinemia (WM).
Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Source: the FDA label for Imbruvica (Pharmacyclics LLC), October 21, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/imbruvica/